Literature DB >> 28074075

Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances.

Gwilym J Webb1, Gideon M Hirschfield1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28074075     DOI： 10.1038/nrgastro.2016.201

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis.

Authors:  Satomi Hisamoto; Shinji Shimoda; Kenichi Harada; Sho Iwasaka; Shinya Onohara; Yong Chong; Minoru Nakamura; Yuki Bekki; Tomoharu Yoshizumi; Toru Ikegami; Yoshihiko Maehara; Xiao-Song He; M Eric Gershwin; Koichi Akashi
Journal:  J Autoimmun       Date:  2016-08-31       Impact factor: 7.094

2.  Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance.

Authors:  Heekyong R Bae; Patrick S C Leung; Koichi Tsuneyama; Julio C Valencia; Deborah L Hodge; Seohyun Kim; Tim Back; Megan Karwan; Anand S Merchant; Nobuyuki Baba; Dechun Feng; Ogyi Park; Bin Gao; Guo-Xiang Yang; M Eric Gershwin; Howard A Young
Journal:  Hepatology       Date:  2016-06-15       Impact factor: 17.425

Review 3.  The immunobiology and pathophysiology of primary biliary cirrhosis.

Authors:  Gideon M Hirschfield; M Eric Gershwin
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

4.  A nontumorigenic variant of FGF19 treats cholestatic liver diseases.

Authors:  Jian Luo; Brian Ko; Michael Elliott; Mei Zhou; Darrin A Lindhout; Van Phung; Carmen To; R Marc Learned; Hui Tian; Alex M DePaoli; Lei Ling
Journal:  Sci Transl Med       Date:  2014-07-30       Impact factor: 17.956

5.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

6.  International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.

Authors:  Heather J Cordell; Younghun Han; George F Mells; Yafang Li; Gideon M Hirschfield; Casey S Greene; Gang Xie; Brian D Juran; Dakai Zhu; David C Qian; James A B Floyd; Katherine I Morley; Daniele Prati; Ana Lleo; Daniele Cusi; M Eric Gershwin; Carl A Anderson; Konstantinos N Lazaridis; Pietro Invernizzi; Michael F Seldin; Richard N Sandford; Christopher I Amos; Katherine A Siminovitch
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

7.  CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver.

Authors:  Ye Htun Oo; Vanessa Banz; Dean Kavanagh; Evaggelia Liaskou; David R Withers; Elizabeth Humphreys; Gary M Reynolds; Laura Lee-Turner; Neena Kalia; Stefan G Hubscher; Paul Klenerman; Bertus Eksteen; David H Adams
Journal:  J Hepatol       Date:  2012-07-14       Impact factor: 25.083

Review 8.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

9.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.

Authors:  Mei Zhou; R Marc Learned; Stephen J Rossi; Alex M DePaoli; Hui Tian; Lei Ling
Journal:  Hepatology       Date:  2015-11-30       Impact factor: 17.425

10.  Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes.

Authors:  Jung-Chin Chang; Simei Go; Dirk R de Waart; Patricia Munoz-Garrido; Ulrich Beuers; Coen C Paulusma; Ronald Oude Elferink
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425
  10 in total
  12 in total

Review 1.  Geoepidemiology and changing mortality in primary biliary cholangitis.

Authors:  Annarosa Floreani; Atsushi Tanaka; Christopher Bowlus; Merrill Eric Gershwin
Journal:  J Gastroenterol       Date:  2017-04-01       Impact factor: 7.527

Review 2.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Authors:  Aliya F Gulamhusein; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-09       Impact factor: 46.802

3.  Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Hung-Wen Chen; Bi-Jhen Syu; Chia-I Lin; Patrick S C Leung; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2018-09-28       Impact factor: 7.094

Review 4.  Clearance of Apoptotic Cells by Tissue Epithelia: A Putative Role for Hepatocytes in Liver Efferocytosis.

Authors:  Scott P Davies; Gary M Reynolds; Zania Stamataki
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

Review 5.  Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?

Authors:  Antonio Molinaro; Hanns-Ulrich Marschall
Journal:  Curr Hepatol Rep       Date:  2017-04-27

6.  Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis.

Authors:  Jin Sung Jang; Brian D Juran; Kevin Y Cunningham; Vinod K Gupta; Young Min Son; Ju Dong Yang; Ahmad H Ali; Elizabeth Ann L Enninga; Jaeyun Sung; Konstantinos N Lazaridis
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

7.  Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio.

Authors:  Jeong-Ju Yoo; Eun Ju Cho; Bora Lee; Sang Gyune Kim; Young Seok Kim; Yun Bin Lee; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

8.  Toward solving the etiological mystery of primary biliary cholangitis.

Authors:  Atsushi Tanakaa; Patrick Sc Leung; Howard A Young; M Eric Gershwin
Journal:  Hepatol Commun       Date:  2017-05-18

9.  Morning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study.

Authors:  Matteo Turco; Nora Cazzagon; Irene Franceschet; Chiara Formentin; Giovanni Frighetto; Francesca Giordani; Nicola Cellini; Gabriella Mazzotta; Rodolfo Costa; Benita Middleton; Debra J Skene; Annarosa Floreani; Sara Montagnese
Journal:  Front Physiol       Date:  2018-11-05       Impact factor: 4.566

10.  Abnormal Expression of ERα in Cholangiocytes of Patients With Primary Biliary Cholangitis Mediated Intrahepatic Bile Duct Inflammation.

Authors:  Hui Cao; Bukun Zhu; Yao Qu; Wei Zhang
Journal:  Front Immunol       Date:  2019-12-05       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.